Estimated Clinical and Economic Burden of Obesity in Japan Over the Next 5 Years

Speaker(s)

Igarashi A1, Capucci S2, Ota R2, Wada S3, Schnecke V2
1The University of Tokyo, Tokyo, Tokyo, Japan, 2Novo Nordisk A/S, Søborg, Denmark, Denmark, 3Novo Nordisk Pharma Ltd., Tokyo, Tokyo, Japan

Presentation Documents

OBJECTIVES: Obesity is a chronic disease with wide-ranging effects on clinical and economic aspects and associated with obesity-related complications (ORCs). Our aim is to quantify the clinical and economic consequences of obesity in the Japanese population.

METHODS: Using population demographics and individual patient-level data from the MDV database of Electronic Medical Records, we constructed a cohort to represent the sub-population with BMI 25-50 kg/m2 and aged 20-69, reflecting the broader Japanese population. The prevalence of 10 ORCs (atrial fibrillation/flutter, asthma, chronic kidney disease, dyslipidaemia, heart failure, hip/knee osteoarthritis, hypertension, sleep apnoea, type 2 diabetes, and unstable angina/myocardial infarction) derived from the MDV data illustrated the clinical burden in this subpopulation living with obesity. Direct yearly treatment costs for the 10 ORCs were obtained from literature and the IQVIA claims database, and used to estimate the economic impact of obesity in Japan. A risk model previously developed from UK EMRs was used to estimate the expected incidence of ORC diagnoses and associated costs for this sub-population over the next 5 years.

RESULTS: Out of Japan's population of 125 million, an estimated 27 million were aged 20-69 with a BMI of 25-50 kg/m2 in 2024. Hypertension, dyslipidaemia, and type 2 diabetes were the most prevalent ORCs, accounting for 30.8%, 17.7%, and 16.6% respectively. The total direct treatment costs for the 10 ORCs in 2024 were estimated at 46.4 billion $, with the highest contributions from type 2 diabetes, unstable angina/myocardial infraction, and heart failure (15.7, 12.8, and 10.5 billion $ respectively). By 2029, the total yearly costs may escalate to 63.4 billion $ due to the increased ORCs prevalence as the population ages.

CONCLUSIONS: In Japan, the economic burden of obesity is estimated to increase by 37% over the coming 5 years, due to increased incidence of ORCs.

Code

EE662

Topic

Economic Evaluation

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity)